Physician profile
Jin Huang
NPI 1669797882
$988.53
in general payments reported to CMS, 2019-2025
12 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $93.28 · 2021: $152 · 2022: $237 · 2023: $129 · 2024: $120 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $357.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $206.85 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $180.55 | 2019-2024 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $113.57 | 2020-2024 | Andexxa |
| Merck Sharp & Dohme LLC | $108.12 | 2019-2024 | Verquvo, Zerbaxa |
| Pfizer INC. | $83.91 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $69.14 | 2022-2023 | |
| Astellas Pharma US INC | $67.08 | 2023-2024 | Cresemba |
| Ucb, INC. | $50.77 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.80 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $27.57 | 2025 | Opsynvi |
| Boston Scientific Corporation | $24.01 | 2025 | Watchman Flx |
| Novo Nordisk INC | $21.16 | 2025 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jin Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.